HPV-010 Subject Treatment Allocation - Cervarix, September 26, 2007

To: Mr. Matthew Whitman
 File: STN 125259/0 CERVARIX
 RE: HPV-010 Subject Treatment Allocation
 Date: September 26, 2007


 Please refer to study HPV-010. Within the meta-analysis for potentially autoimmune events, subject PID #1658, who received either Gardasil or Cervarix, developed possible MS at 33 days after dose 2 of blinded study material. We acknowledge that the study is ongoing, but please provide the treatment allocation for this subject by the unblinded statistician as soon as possible.
